iData Insights

Small-Cell Lung Cancer - Pipeline Review, H2 2015Now Available at iData Insights

Press Release   •   Jan 23, 2016 14:52 IST

Small-Cell Lung Cancer - Pipeline Review, H2 2015 Summary Global Markets Direct s, Small-Cell Lung Cancer - Pipeline Review, H2 2015, provides an overview of the Small-Cell Lung Cancers therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Small-Cell Lung Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Small-Cell Lung Cancer and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Small-Cell Lung Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Small-Cell Lung Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Small-Cell Lung Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Small-Cell Lung Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Small-Cell Lung Cancer - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Small-Cell Lung Cancer pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Browsewith TOC @ http://www.idatainsights.com/reports-landing-page.php?id=173364/small-cell-lung-cancer-pipeline-review-h2-2015

To Get Sample Copy of Report visit @http://www.idatainsights.com/reports-landing-page.php?id=173364/small-cell-lung-cancer-pipeline-review-h2-2015

Table of Contents

Introduction 12

Global Markets Direct Report Coverage 12

Myelodysplastic Syndrome Overview 13

Therapeutics Development 14

Pipeline Products for Myelodysplastic Syndrome - Overview 14

Pipeline Products for Myelodysplastic Syndrome - Comparative Analysis 15

Myelodysplastic Syndrome - Therapeutics under Development by Companies 16

Myelodysplastic Syndrome - Therapeutics under Investigation by Universities/Institutes 23

Myelodysplastic Syndrome - Pipeline Products Glance 24

Late Stage Products 24

Clinical Stage Products 25

Early Stage Products 26

Myelodysplastic Syndrome - Products under Development by Companies 27

Myelodysplastic Syndrome - Products under Investigation by Universities/Institutes 35

Myelodysplastic Syndrome - Companies Involved in Therapeutics Development 36

4SC AG 36

Acceleron Pharma, Inc. 37

Actinium Pharmaceuticals, Inc. 38

Advancell 39

Agios Pharmaceuticals, Inc. 40

Alnylam Pharmaceuticals, Inc. 41

Altor BioScience Corporation 42

Amgen Inc. 43

Apogenix GmbH 44

Arno Therapeutics, Inc. 45

Arog Pharmaceuticals, Inc. 46

Array BioPharma Inc. 47

Astex Pharmaceuticals, Inc. 48

Atara Biotherapeutics, Inc. 49

Bellicum Pharmaceuticals, Inc. 50

Bio-Path Holdings, Inc. 51

BioLineRx, Ltd. 52

Boehringer Ingelheim GmbH 53

Boryung Pharmaceutical Co., Ltd. 54

Boston Biomedical, Inc. 55

Bristol-Myers Squibb Company 56

Celator Pharmaceuticals, Inc. 57

Celgene Corporation 58

Celldex Therapeutics, Inc. 59

Cellerant Therapeutics, Inc. 60

Celyad SA 61

Clevexel Pharma SAS 62

Concert Pharmaceuticals, Inc. 63

Constellation Pharmaceuticals, Inc. 64

Cornerstone Pharmaceuticals, Inc. 65

CrystalGenomics, Inc. 66

CTI BioPharma Corp. 67

Cyclacel Pharmaceuticals, Inc. 68

Daiichi Sankyo Company, Limited 69

DiNonA Inc. 70

Eisai Co., Ltd. 71

Eleos Inc. 72

Eli Lilly and Company 73

EpiZyme, Inc. 74

F. Hoffmann-La Roche Ltd. 75

FORMA Therapeutics, Inc. 76

Fujifilm Corporation 77

Gamida Cell Ltd. 78

IGF Oncology, LLC. 79

ImmunoGen, Inc. 80

Incyte Corporation 81

Juno Therapeutics Inc. 82

JW Pharmaceutical Corporation 83

Kainos Medicine, Inc. 84

KaloBios Pharmaceuticals, Inc. 85

Karyopharm Therapeutics, Inc. 86

Kiadis Pharma B.V. 87

Kyowa Hakko Kirin Co., Ltd. 88

Les Laboratoires Servier SAS 89

Lixte Biotechnology Holdings, Inc. 90

medac GmbH 91

MedImmune, LLC 92

MEI Pharma, Inc. 93

Merck & Co., Inc. 94

Merus B.V. 95

Millennium Pharmaceuticals, Inc. 96

Mirati Therapeutics Inc. 97

Mirna Therapeutics, Inc. 98

Nemucore Medical Innovations, Inc. 99

Novartis AG 100

Onconova Therapeutics, Inc. 101

Opsona Therapeutics Limited 102

OXiGENE, Inc. 103

Pfizer Inc. 104

Pharma Mar, S.A. 105

Regen BioPharma, Inc. 106

Rich Pharmaceuticals, Inc. 107

Stemline Therapeutics, Inc. 108

Sumitomo Dainippon Pharma Co., Ltd. 109

Sunesis Pharmaceuticals, Inc. 110

Syndax Pharmaceuticals, Inc. 111

Synta Pharmaceuticals Corp. 112

Targazyme, Inc. 113

TetraLogic Pharmaceuticals 114

Teva Pharmaceutical Industries Limited 115

Threshold Pharmaceuticals, Inc. 116

Tragara Pharmaceuticals, Inc. 117

Myelodysplastic Syndrome - Therapeutics Assessment 118

Assessment by Monotherapy Products 118

Assessment by Combination Products 119

Assessment by Target 120

Assessment by Mechanism of Action 128

Assessment by Route of Administration 135

Assessment by Molecule Type 137

Drug Profiles 139

(cytarabine hydrochloride + daunorubicin hydrochloride) - Drug Profile 139

(decitabine + E-7727) - Drug Profile 142

4SC-202 - Drug Profile 144

765IGF-MTX - Drug Profile 146

acadesine - Drug Profile 147

AG-120 - Drug Profile 149

ALN-HPN - Drug Profile 151

alpelisib - Drug Profile 152

ALT-803 - Drug Profile 154

Antisense RNAi Oligonucleotide to Inhibit NR2F6 Protein for Oncology - Drug Profile 157

AR-42 - Drug Profile 158

asinercept - Drug Profile 160

atezolizumab - Drug Profile 162

ATIR-101 - Drug Profile 166

azacitidine - Drug Profile 168

BBMPI-03 - Drug Profile 172

BI-836858 - Drug Profile 173

binimetinib - Drug Profile 174

birinapant - Drug Profile 179

BL-8040 - Drug Profile 182

BLI-1301 - Drug Profile 184

bortezomib - Drug Profile 185

BP-100101 - Drug Profile 191

BPX-501 - Drug Profile 193

BR-05001 - Drug Profile 195

CC-90007 - Drug Profile 196

CDX-1401 - Drug Profile 199

Cell Therapy to Target Tumor Associated Antigen for Hematopoietic Malignancies - Drug Profile 201

Cell Therapy to Target WT-1, NY-ESO-1, PRAME and Survivin for Oncology - Drug Profile 202

Cell Therapy to Target WT1 for Cancer - Drug Profile 203

cenersen sodium - Drug Profile 204

CG-200745 - Drug Profile 206

CIGB-300 - Drug Profile 207

CMCS-1 - Drug Profile 209

CPI-0610 - Drug Profile 211

CPI-613 - Drug Profile 212

crenolanib besylate - Drug Profile 214

CSC-012 - Drug Profile 216

CTP-221 - Drug Profile 217

CVXL-0056 - Drug Profile 218

CWP-291 - Drug Profile 219

darbepoetin alfa - Drug Profile 221

dasatinib - Drug Profile 223

decitabine - Drug Profile 226

Dendritic Cell Therapy for Hematological Malignancies - Drug Profile 229

Dendritic Cell Therapy for Oncology - Drug Profile 230

Dendritic Cell Therapy to Target WT1 for Oncology - Drug Profile 231

DNP-001 - Drug Profile 232

DS-3032 - Drug Profile 233

DSP-7888 - Drug Profile 234

durvalumab - Drug Profile 235

E-6201 - Drug Profile 239

eltrombopag olamine - Drug Profile 241

entinostat - Drug Profile 244

epacadostat - Drug Profile 248

erismodegib - Drug Profile 250

everolimus - Drug Profile 253

evofosfamide - Drug Profile 259

FF-10501 - Drug Profile 267

FT-1101 - Drug Profile 268

galunisertib - Drug Profile 269

ganetespib - Drug Profile 271

Gene Therapy for Oncology - Drug Profile 276

glasdegib - Drug Profile 277

guadecitabine - Drug Profile 279

HDM-201 - Drug Profile 283

Hu8F4 - Drug Profile 284

IMGN-779 - Drug Profile 285

indisulam - Drug Profile 286

Iomab-B - Drug Profile 288

ixazomib citrate - Drug Profile 290

JTCR-016 - Drug Profile 294

KB-004 - Drug Profile 295

KHK-2823 - Drug Profile 297

KM-101 - Drug Profile 298

LB-100 - Drug Profile 299

lenalidomide - Drug Profile 301

lirilumab - Drug Profile 306

lurbinectedin - Drug Profile 308

luspatercept - Drug Profile 311

MCLA-?117 - Drug Profile 313

midostaurin - Drug Profile 314

mocetinostat - Drug Profile 316

Monoclonal Antibodies to Target CD16 and CD33 for Oncology - Drug Profile 319

Monoclonal Antibody Conjugate 2 to Target CD45 for Cancer - Drug Profile 320

Monoclonal Antibody Conjugate to Inhibit Protein S100-A9 for MDS - Drug Profile 321

Monoclonal Antibody Conjugate to Target CD45 for Oncology - Drug Profile 322

Monoclonal Antibody for Myelodysplastic Syndrome - Drug Profile 323

MRX-102 - Drug Profile 324

MRX-34 - Drug Profile 326

napabucasin - Drug Profile 328

NiCord - Drug Profile 331

NMI-900 - Drug Profile 332

omacetaxine mepesuccinate - Drug Profile 333

ONC-201 - Drug Profile 336

OPN-305 - Drug Profile 339

OXi-4503 - Drug Profile 341

pacritinib - Drug Profile 343

pembrolizumab - Drug Profile 346

pevonedistat hydrochloride - Drug Profile 355

pexmetinib - Drug Profile 357

PIM-447 - Drug Profile 358

pinometostat - Drug Profile 359

pracinostat - Drug Profile 362

quizartinib dihydrochloride - Drug Profile 364

rigosertib sodium - Drug Profile 367

RP-323 - Drug Profile 372

ruxolitinib phosphate - Drug Profile 373

S-055746 - Drug Profile 378

sapacitabine - Drug Profile 379

selinexor - Drug Profile 381

SL-401 - Drug Profile 387

Small Molecule to Inhibit KDM1A for Oncology - Drug Profile 389

Small Molecule to Inhibit SF3B1 for myelodysplastic syndrome - Drug Profile 390

Small Molecules for Oncology - Drug Profile 391

sotatercept - Drug Profile 392

TEN-010 - Drug Profile 394

TG-02 - Drug Profile 395

tosedostat - Drug Profile 398

trametinib dimethyl sulfoxide - Drug Profile 400

treosulfan - Drug Profile 403

TZ-101 - Drug Profile 405

ulixertinib - Drug Profile 407

Vaccine for Oncology - Drug Profile 408

Vaccine to Target Wilms Tumor Protein for Oncology - Drug Profile 409

Vaccine to Target WT1 for Oncology - Drug Profile 410

VAL-1000 - Drug Profile 411

volasertib - Drug Profile 412

vorinostat - Drug Profile 415

vosaroxin - Drug Profile 419

WT-4869 - Drug Profile 421

Myelodysplastic Syndrome - Recent Pipeline Updates 422

Myelodysplastic Syndrome - Dormant Projects 662

Myelodysplastic Syndrome - Discontinued Products 667

Myelodysplastic Syndrome - Product Development Milestones 669

Featured News & Press Releases 669

Appendix 675

Methodology 675

Coverage 675

Secondary Research 675

Primary Research 675

Expert Panel Validation 675

Contact Us 675

Disclaimer 676

Read More http://www.idatainsights.com/reports-landing-page.php?id=173364/small-cell-lung-cancer-pipeline-review-h2-2015

About Us:

iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line.

ContactUs:
iData Insights

Tel: 1-866-237-2965

Web: http://www.idatainsights.com
Email: info@idatainsights.com

AboutiData Insights

We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future projects